NCT07181473View on ClinicalTrials.gov

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 25, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

September 15, 2027

Conditions
Lung Cancer (NSCLC)Prostate CancerEsophageal CancerSolid Tumor Malignancies
Interventions
DRUG

TJ101

TJ101 is a EGFR/B7H3 directed antibody conjugate with a cleavable linker and a noval topoisomerase I inhibitor.

Trial Locations (5)

77030

NOT_YET_RECRUITING

Oncology Consultants, Houston

Unknown

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

NOT_YET_RECRUITING

Union Hospital of Tongji Medical College, Wuhan

NOT_YET_RECRUITING

Sir Run Run Shaw Hospital, Hangzhou

RECRUITING

Shanghai East Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Phrontline Biopharma

INDUSTRY